Peter B. Rahl

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index17.4kcitations104works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(48), Microtubule and mitosis dynamics(25), Multiple Myeloma Research and Treatments(24), Genomics and Chromatin Dynamics(16), RNA Research and Splicing(16)

Publications104 total

Figure S7 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S5 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S2 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S13 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S4 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S3 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S11 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S6 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S4 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S2 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S9 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S12 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S10 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S8 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S5 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S3 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S7 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Table S6 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
Figure S1 from Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma
2026Open Access
page 1 of 6Next →

Frequent Co-authors

Richard A. Young(22), Nikolaus D. Obholzer(13), Wayne L. Glore(12), Charles Y. Lin(11), Yaretzi Calderón(11), Jessica Encinas(11), Minyun Zhou(11), Marek J. Kobylarz(10), Tamara D. Hopkins(10), Jun Qi(6), James E. Bradner(6), Ruth Collins(6), Giulia Giorgetti(6), W. Frank Lenoir(6), Michael R. McKeown(6), Luis A. Carvajal(6), Kameron R. Mori(6), Jun Li(6), Hua Gao(6), Yupeng Zheng(6)